Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 5;3(2):100219.
doi: 10.1016/j.jhepr.2020.100219. eCollection 2021 Apr.

Case-finding strategies in non-alcoholic fatty liver disease

Jerome Boursier  1   2 , Emmanuel A Tsochatzis  3   4
Affiliations
Review

Case-finding strategies in non-alcoholic fatty liver disease

Jerome Boursier et al. JHEP Rep. .

Abstract

Among the large population of patients with non-alcoholic fatty liver disease (NAFLD), identifying those with advanced disease remains challenging. Many patients are diagnosed late, following the development of liver-related complications, leading to poor clinical outcomes. Accumulating evidence suggests that using non-invasive tests for liver fibrosis in patients with metabolic risk factors improves the detection of patients in need of specialised management and is cost-effective. Because of the vast number of patients requiring evaluation, the active participation of general practitioners and physicians who manage patients with metabolic disorders, such as diabetologists, is crucial; this calls for the increased awareness of NAFLD beyond liver clinics. Non-invasive case-finding strategies will need to be further validated and generalised for upcoming drug therapies to have the required impact on the worldwide burden of NAFLD.

Keywords: ALD, alcohol-related liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Awareness; Case-finding; Cirrhosis; Cost-effectiveness; ELF, enhanced liver fibrosis; Elastography; FIB-4; FIB-4, fibrosis-4; GP, general practitioner; Liver fibrosis; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; NASH, non-alcoholic steatohepatitis; NFS, NAFLD fibrosis score; NICE, National Institute of Clinical Excellence; NIT, non-invasive test; Patient pathway; Primary care; QALY, quality-adjusted life year; Screening; T2DM, type 2 diabetes mellitus; TE, transient elastography; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

J Boursier has consulting activities and received support for research from Echosens and Siemens. E Tsochatzis has no relevant conflicts of interest to declare. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

Fig. 1
Fig. 1
Populations at risk of NAFLD-related liver outcomes. NAFLD, non-alcoholic fatty liver disease.
Fig. 2
Fig. 2
Non-invasive tests for liver fibrosis. MRE, magnetic resonance elastography; SWE, shearwave elastography; VCTE, vibration controlled transient elastography.
Fig. 3
Fig. 3
Testing pathway for patients with a diagnosis of NAFLD in non-hepatology specialties. An initial FIB-4 is followed by elastography or a patented serum non-invasive test such as ELF or FibroMeter. The target lesion is the presence of advanced fibrosis. NIT, non-invasive test.
See this image and copyright information in PMC

References

    1. Younossi Z.M., Stepanova M., Afendy M., Fang Y., Younossi Y., Mir H. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530. e521; quiz e560. - PubMed
    1. Setiawan V.W., Stram D.O., Porcel J., Lu S.C., Le Marchand L., Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology. 2016;64:1969–1977. - PMC - PubMed
    1. Dyson J., Jaques B., Chattopadyhay D., Lochan R., Graham J., Das D. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–117. - PubMed
    1. Haldar D., Kern B., Hodson J., Armstrong M.J., Adam R., Berlakovich G. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study. J Hepatol. 2019;71:313–322. - PMC - PubMed
    1. Goldberg D., Ditah I.C., Saeian K., Lalehzari M., Aronsohn A., Gorospe E.C. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152:1090–1099 e1091. - PMC - PubMed

LinkOut - more resources